Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 8Terminated 3Recruiting 2Unknown 1

Sponsor Class

OTHER 3INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 2Gastrointestinal 1

Conditions

Neoplasms 473Carcinoma, Non-Small-Cell Lung 447Breast Neoplasms 331Neoplasm Metastasis 242Colorectal Neoplasms 214Melanoma 213Leukemia, Myeloid, Acute 191Multiple Myeloma 180Recurrence 169Ovarian Neoplasms 169Prostatic Neoplasms 163Lymphoma, Non-Hodgkin 148Lung Neoplasms 134Pancreatic Neoplasms 125Lymphoma 123Carcinoma, Renal Cell 112Squamous Cell Carcinoma of Head and Neck 110Leukemia, Lymphocytic, Chronic, B-Cell 110Stomach Neoplasms 92Carcinoma, Hepatocellular 89Lymphoma, Large B-Cell, Diffuse 88Leukemia 87Triple Negative Breast Neoplasms 86Lymphoma, Follicular 82Head and Neck Neoplasms 79Glioblastoma 74Myelodysplastic Syndromes 70Urinary Bladder Neoplasms 68Small Cell Lung Carcinoma 64Precursor Cell Lymphoblastic Leukemia-Lymphoma 55

Interventions

Megestrol Acetate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × INDUSTRY × Anorexia × Clear all
NCT00637728 2016-06-23

Treatment of Cancer-anorexia Using Megestrol Acetate Concentrated Suspension in Lung or Pancreatic Cancer Patients

Par Pharmaceutical, Inc.

Phase 3 Terminated
5 enrolled 8 charts
GastrointestinalThoracic

Anorexia, Body Weight, Cachexia, Lung Neoplasms, Pancreatic Neoplasms, Weight Loss

NCT00637806 2016-05-02

Treatment of Cancer-associated Anorexia Using Megestrol Acetate Concentrated Suspension

Par Pharmaceutical, Inc.

Phase 3 Terminated
4 enrolled 6 charts

Anorexia, Body Weight, Cachexia, Neoplasms, Weight Loss

NCT00535015 2008-07-22

Safety and Efficacy Study of Betamarc to Treat Loss of Weight and Appetite in Non-Small Cell Lung Cancer

Anaborex

Phase 2 Terminated
70 enrolled
Thoracic

Anorexia, Cachexia, Carcinoma, Non-Small-Cell Lung, Weight Loss

Data powered by HemOnc (CC BY 4.0) Colophon âš¡